PHP
SVRA icon

Parkman Healthcare Partners’s Savara SVRA Stock Holding History

Parkman Healthcare Partners’s Portfolio SVRA Stock Details SVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-206,607
Closed -$660K – 111
2023
Q2 		$660K Buy
206,607
+29,364
+17% +$69K 0.11% 92
2023
Q1 		$346K Buy
+177,243
New +$399K 0.08% 82

Other funds holding SVRA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Parkman Healthcare Partners's SVRA Position: Q3 2023 in Review

Parkman Healthcare Partners sold out of Savara (SVRA) in Q3 2023, closing a stake of 206,607 shares — an estimated $660K sold.

Parkman Healthcare Partners first reported a position in SVRA in Q1 2023 and held it in 2 quarters. The position peaked at $660K in Q2 2023. 84 funds tracked by Wall St. Rank hold SVRA as of Q3 2023.

  • Parkman Healthcare Partners reported no remaining Savara position as of Q3 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 206,607 Savara shares in Q3 2023, an estimated $660K.
  • Parkman Healthcare Partners first reported a position in Savara in Q1 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's Savara position peaked at $660K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held Savara as of Q3 2023.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.